Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma | Synapse
March 3, 2026
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma
SS
Sergi V. Salsench
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
GF
Gerardo Ferrer
Universidad de la República de Uruguay
AO
Almudena Garcia Ortiz
Ver todo
Puntos clave
PVR (CD155) epigenetic status directly influences immunotherapy response.
The study highlights a potential average survival difference of 12 months based on epigenetic modifications.
Analysis reveals varying PVR (CD155) expression levels in multiple myeloma patients undergoing treatment.
Understanding PVR (CD155) epigenetics may lead to improved immunotherapy strategies and patient outcomes.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Salsench et al. (Tue,) studied this question.
synapsesocial.com/papers/69a75e5ec6e9836116a28db9
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir